Optimal treatment of the diabetic patient with multivessel disease

Current Cardiology Reports

Volumn 10, Issue 4, 2008, Pages 272-284

  Bansilal, Sameer ^a   Farkouh, Michael E ^a   Fuster, Valentin ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CHLOROTHIAZIDE; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FIBRINOGEN RECEPTOR ANTAGONIST; GEMFIBROZIL; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; METOPROLOL; NICOTINIC ACID; NISOLDIPINE; PERINDOPRIL; PIOGLITAZONE; PLACEBO; PRASUGREL; RAMIPRIL; ROSIGLITAZONE; SIMVASTATIN; SULFONYLUREA DERIVATIVE; TELMISARTAN; UNINDEXED DRUG; ANTITHROMBOCYTIC AGENT; HYPOCHOLESTEROLEMIC AGENT;

ADD ON THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; DIABETES CONTROL; DIABETIC DIET; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG CHOICE; DRUG EFFICACY; DRUG ELUTING STENT; DRUG TOLERABILITY; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; EXERCISE; GLYCEMIC CONTROL; HEART INFARCTION; HOT FLUSH; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; KIDNEY FAILURE; LIFESTYLE MODIFICATION; LOADING DRUG DOSE; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; RISK REDUCTION; SMOKING CESSATION; TRANSLUMINAL CORONARY ANGIOPLASTY; WEIGHT REDUCTION; ARTICLE; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HYPERLIPIDEMIA; METABOLISM; PATHOLOGY; RISK FACTOR;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICHOLESTEREMIC AGENTS; BLOOD GLUCOSE; CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; PLATELET AGGREGATION INHIBITORS; RISK FACTORS;

EID: 54449094896     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-008-0045-x     Document Type: Review

References (64)

1. Bonow RO, GheorghAade M: The diabetes epidemic: a national and global crisis. Am J Med 2004, 116(Suppl 5A): 2S-10S.
2. Hogan P, Dall T, Nikolov P; American Diabetes Association: Economic costs of diabetes in the US in 2002. Diabetes Care 2003, 26: 917-932.
3. Mokdad AH, Bowman BA, Ford ES, et al.: The continuing epidemics of obesity and diabetes in the United States. JAMA 2001, 286: 1195-1200.
4. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16: 434-444.
5. Barsness GW, Peterson ED, Ohman EM, et al.: Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation 1997, 96: 2551-2556.
6. Waller BF, Palumbo PJ, Lie JT, Roberts WC: Status of the coronary arteries at necropsy in diabetes mellitus with onset after age 30 years: analysis of 229 diabetic patients with and without clinical evidence of coronary heart disease and comparison to 183 control subjects. Am J Med 1980, 69: 498-506.
7. Silva JA, EAcobar A, Collins TJ, et al.: Unstable angina: a comparison of angioscopic findings between diabetic and nondiabetic patients. Circulation 1995, 92: 1731-1736.
8. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352: 837-853.
9. Dormandy JA, Charbonnel B, Eckland DJ, et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366: 1279-1289.
10. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356: 2457-2471.
11. Home PD, Pocock SJ, Beck-Nielsen H, et al.: Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007, 357: 28-38.
12. US Food and Drug Administration: FDA Adds Boxed Warning for Heart-related Risks to Anti-Diabetes Drug Avandia. http://www.fda.gov/ bbs/topics/NEWS/2007/NEW01743.html. Accessed April 10, 2008.
13. National Heart and Lung Institute: Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. http://www.nhlbi.nih.gov/health/prof/heart/ other/accord/index.htm.
14. Patel A; ADVANCE Collaborative Group, et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial). Lancet 2007, 6736: 61303-61308.
15. Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet 1998, 351: 1755-1762.
16. Tuomilehto J, Rastenyte D, Birkenhager WH, et al.: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999, 340: 677-684.
17. Estacio RO, Jeffers BW, Gifford N, Schrier RW: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000, 23(Suppl 2): B54-B64.
18. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE study [no authors listed]. Lancet 2000, 355: 253-259.
19. Bakris GL, Fonseca V, Katholi RE, et al.: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial. JAMA 2004, 292: 2227-2236.
20. Teo K, Yusuf S, Sleight P, et al.: Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004, 148: 52-61.
21. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: Scandinavian Simvastatin Survival Study (4S) [no authors listed]. Lancet 1994, 344: 1383-1389.
22. Goldberg RB, Mellies MJ, Sacks FM, et al.: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial: the CARE investigators. Circulation 1998, 98: 2513-2519.
23. Collins R, Armitage J, Parish S, et al.: Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004, 363: 757-767.
24. Colhoun HM, Betteridge DJ, Durrington PN, et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 2004, 364: 685-696.
25. Wanner C, Krane V, Marz W, et al.: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353: 238-248.
26. Kearney PM, Blackwell L, Collins R, et al.: Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet 2008, 371: 117-125.
27. Rubins HB, Robins SJ, Collins D, et al.: Diabetes, plasma insulin, and cardiovascular disease: Subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002, 162: 2597-2604.
28. Keech A, Simes RJ, Barter P, et al.: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2005, 366: 1849-1861.
29. AIM-HIGH Clinical Study. http://accelerator.axioresearch.com/aim-high/. Accessed April 10, 2008.
30. ClinicalTrials.gov: A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension. http://www.clinicaltrial.gov/ct2/show/ NCT00461630. Accessed April 10, 2008.
31. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324: 71-86.
32. Steinhubl SR, Berger PB, Mann JT 3rd, et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 288: 2411-2420.
33. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee [no authors listed]. Lancet 1996, 348: 1329-1339.
34. Yusuf S, Zhao F, Mehta SR, et al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndrome without ST-segment elevation. N Engl J Med 2001, 345: 494-502.
35. Diener HC, Bogousslavsky J, Brass LM, et al.: Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet 2004, 364: 331-337.
36. Wiviott SD, Braunwald E, McCabe CH, et al.: Prasugrel vs clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357: 2001-2015.
37. Bhatt DL, Marso SP, Lincoff AM, et al.: Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000, 35: 922-928.
38. Anderson KM, Califf RM, Stone GW, et al.: Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2001, 37: 2059-2065.
39. Roffi M, Chew DP, Mukherjee D, et al.: Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2001, 104: 2767-2771.
40. Lincoff AM, Bittl JA, Harrington RA, et al.: Bivalirudin and provisional glycoprotein IIbIIIa blockade compared with heparin and planned glycoprotein IIbIIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003, 289: 853-863.
41. Gaede P, Lund-Anderson H, Parving HH, et al.: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358: 580-591.
42. Ryan DH, Espeland MA, Foster GD, et al.: Look AHEAD (Action for Health in Diabetes): Design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials 2003, 24: 610-628.
43. Chaturvedi N, Stevens L, Fuller JH: Which features of smoking determine mortality risk in former cigarette smokers with diabetes? The World Health Organization Multinational Study Group. Diabetes Care 1997, 20: 1266-1272.
44. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators [no authors listed]. N Engl J Med 1996, 335: 217-225.
45. Detre KM, Guo P, Holubkov R, et al.: Coronary revascularization in diabetic patients: A comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1999, 99: 633-640.
46. King SB 3rd, Kosinski AS, Guyton RA, et al.: Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST). J Am Coll Cardiol 2000, 35: 1116-1121.
47. Kurbaan AS, Bowker TJ, Ilsley CD, et al.: Difference in the mortality of the CABRI diabetic and nondiabetic populations and its relation to coronary artery disease and the revascularization mode. Am J Cardiol 2001, 87: 947-950; A3.
48. Barsness GW, Peterson ED, Ohman EM, et al.: Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation 1997, 96: 2551-2556.
49. Serruys PW, Ong AT, van Herwerden LA, et al.: Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: The final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol 2005, 46: 575-581.
50. Pepper JR: The stent or surgery trial longer-term follow-up. Presented at the World Congress of Cardiology [presentation 3466]. Barcelona, Spain; September 4, 2006.
51. Rodriguez AE, Baldi J, Fernandez Pereira C, et al.: Five-year follow-up of the Argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel disease (ERACI II). J Am Coll Cardiol 2005, 46: 582-588.
52. Soares PR, Hueb WA, Lemos PA, et al.: Coronary revascularization (surgical or percutaneous) decreases mortality after the first year in diabetic subjects but not in nondiabetic subjects with multivessel disease: An analysis from the Medicine, Angioplasty, or Surgery Study (MASS II). Circulation 2006, 114(1 Suppl): I420-I424.
53. Morrison DA, Sethi G, Sacks J, et al.: Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: A multicenter, randomized trial. Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). J Am Coll Cardiol 2001, 38: 143-149.
54. Hannan EL, Racz MJ, Walford G, et al.: Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med 2005, 352: 2174-2183.
55. Roiron C, SanchAz P, Bouzamondo A, et al.: Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart 2006, 92: 641-649.
56. Kuchulakanti PK, Chu WW, Torguson R, et al.: Sirolimus-eluting stents versus Paclitaxel-eluting stents in the treatment of coronary artery disease in patients with diabetes mellitus. Am J Cardiol 2006, 98: 187-192.
57. Hannan EL, Wu C, Walford G, et al.: Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. N Engl J Med 2008, 358: 331-341.
58. Sobel BE, Frye R, Detre KM: Burgeoning dilemmas in the management of diabetes and cardiovascular disease: Rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation 2003, 107: 636-642.
59. Ong AT, Serruys PW, Mohr FW, et al.: The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase. Am Heart J 2006, 151: 1194-1204.
60. Kapur A, Malik IS, Bagger JP, et al.: The Coronary Artery Revascularisation in Diabetes (CARDia) trial: Background, aims, and design. Am Heart J 2005, 149: 13-19.
61. Farkouh ME, Dangas G, Leon MB, et al.: Design of the Future R Evascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. Am Heart J 2008, 155: 215-223.
62. ClinialTrials.gov: Coronary Artery Revascularization in Diabetes. http://clinicaltrials.gov/ct/show/NCT00326196?order=1. Accessed April 10, 2008.
63. Ong KL, Cheung BM, Wong LY, et al.: Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004. Ann Epidemiol 2008, 18: 222-229.
64. American Diabetes Association: Standards of medical care in diabetes - 2007. Diabetes Care 2007, 30(Suppl 1): S4-S41.